View source for 36ly


==Crystal Structure of mini-binder MB07==
<StructureSection load='36ly' size='340' side='right'caption='[[36ly]], [[Resolution|resolution]] 2.55&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[36ly]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=36LY OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=36LY FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.55&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=36ly FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=36ly OCA], [https://pdbe.org/36ly PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=36ly RCSB], [https://www.ebi.ac.uk/pdbsum/36ly PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=36ly ProSAT]</span></td></tr>
</table>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Toxigenic bacterial infections in the gut are a significant contributor to the global burden of disease. Advanced tools for protein and live biotherapeutic engineering offer potentially transformative strategies for treating such diseases, while avoiding the collateral effects of traditional antibacterials. Here we used de novo protein design to identify inhibitors of the metzincin family protease Bacteroides fragilis toxin (BFT). These inhibitors, which bind distal to the active site, interfere with toxin-mediated E-cadherin cleavage and downstream proinflammatory signaling by blocking claudin-4 receptor binding. We tested the inhibitors as disulfide-stabilized variants administered directly to the cecum or in drinking water, as well as through in situ secretion by an engineered live biotherapeutic. Across these delivery modalities, the inhibitors successfully neutralized the toxin and effectively prevented BFT-associated gut pathology, including tumor formation. These results highlight the potential of de novo designed proteins as precise, non-antibiotic interventions to mitigate bacterial toxin-driven disease in the gut.

Orally available designed miniproteins inhibit enterotoxigenic Bacteroides fragilis pathology by blocking toxin receptor binding.,Srinivas P, Adebomi V, Markiewicz SM, Wang K, Chac D, Lindenauer K, Huber N, Tao Z, Luong P, Rettie SA, Smith MW, Bera AK, Kang A, Nguyen H, Schneider M, Wang Y, Peterson SB, Dong M, Weil AA, Bhardwaj G, Mougous JD bioRxiv [Preprint]. 2026 Jun 23:2026.06.22.733822. doi: , 10.64898/2026.06.22.733822. PMID:42395444<ref>PMID:42395444</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 36ly" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Large Structures]]
[[Category: Synthetic construct]]
[[Category: Adebomi V]]
[[Category: Bera AK]]
[[Category: Bhardwaj G]]
[[Category: Kang A]]
[[Category: Srinivas P]]